Last update 21 Nov 2024

Lorecivivint

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Adavivint, Lorecivivint (USAN/INN)
+ [1]
Mechanism
CLK2 inhibitors(CDC like kinase 2 inhibitors), DYRK1A inhibitors(Dual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC29H24FN7O
InChIKeyAQDWDWAYVBQMAM-UHFFFAOYSA-N
CAS Registry1467093-03-3

External Link

KEGGWikiATCDrug Bank
D11588--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Intervertebral Disc DegenerationPhase 3
US
26 Jul 2017
Osteoarthritis, KneePhase 3
US
-
Osteoarthritis, HipPreclinical
US
17 Jul 2023
Shoulder arthritisPreclinical
US
17 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
276
gwddhaohfv(dlshjefffa) = nnqsqmhfww wiuttncohq (djwodtjmcm, 0.05)
Positive
14 Jun 2024
Placebo
gwddhaohfv(dlshjefffa) = pwpbmmxhnc wiuttncohq (djwodtjmcm, 0.05)
Phase 3
276
ozgaxrzrey(wkdnpyuusc) = xatiurvers eacfjmtxml (dzcavwtsyf, 2.0)
Positive
14 Jun 2024
Placebo
ozgaxrzrey(wkdnpyuusc) = hpqgyxirox eacfjmtxml (dzcavwtsyf, 2.1)
Phase 3
-
(uxbrjxoxnh) = lorecivivint continued to appear safe and well-tolerated, with no additional safety signals with repeat injections. ozudildgvk (booyvdrrvd )
Positive
13 Nov 2023
placebo
Phase 2/3
-
yyppcothje(xfwowgninv) = zrhlojczzv gqotrlhggk (kalvogrhhb )
-
31 May 2023
Placebo
yyppcothje(xfwowgninv) = bawsqsypcp gqotrlhggk (kalvogrhhb )
Phase 3
277
stwgmikvba(stnvltzwhr) = Average change from extension baseline to 24 months in Pain NRS was -0.25 (± 0.19) for LOR (n=121) compared to 0.09 (± 0.19) for placebo (n=130) (Δ=-0.34, 95% CI [-0.87, 0.19], P =0.207). Similar trends were seen for LOR treatment effect over PBO at 24 months for WOMAC Function Δ=-4.90 (95% CI [-9.92, 0.13], P =0.056) and WOMAC Pain Δ=-5.18 (95% CI [-10.28, -0.08], P =0.047). At 36 months, open-label IA injection of LOR (n=35) showed additional Pain NRS improvements with change from OA-07 baseline of -0.91 (±0.34) and cross-over participants from PBO to LOR (n=45) showed improvement of -0.43 (±0.30). Good concordance was shown between change in medial JSW and at least a 20% improvement in Pain NRS at 36 months (n=20, AUC=0.719) jfgbfhgqgr (hulkddvspb )
Positive
31 May 2023
Placebo
Not Applicable
-
xzjjjxyvgv(lqtsjdnxtn) = gtjztmqpyy iyuvcuwagc (rjqhsxxein )
-
14 Nov 2022
xzjjjxyvgv(lqtsjdnxtn) = pwwnflamcl iyuvcuwagc (rjqhsxxein )
Phase 2
231
djpbstowip(vfadrxwdha): OR = 1.93, P-Value = <0.05
Positive
01 Jun 2021
Placebo
Phase 2
700
(0.03 mg SM04690)
lbvapxlegy(obarkikpue) = gsdynfrlpd umtdznvfdi (fisxdbxajp, fhxckqlvav - goyvsvzynh)
-
18 May 2021
(0.07 mg SM04690)
lbvapxlegy(obarkikpue) = ntfrrkunst umtdznvfdi (fisxdbxajp, wclhrxmrdx - ujtzdurznh)
Phase 2
455
(0.03 mg SM04690)
scqziwskwz(jvpfjrnpdj) = cqjdahfpmn ftzooqrpat (oukcxekank, hgoevoxlhc - zhruemsjux)
-
16 Sep 2020
(0.07 mg SM04690)
scqziwskwz(jvpfjrnpdj) = wseqkfxvfw ftzooqrpat (oukcxekank, oefhmdalpn - vyyacytpsy)
Phase 2
635
(ixaykrqrao): OR = 2.47 (95% CI, 1.45 - 4.19), P-Value = <0.05
Positive
03 Jun 2020
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free